Cerebellar transcranial magnetic stimulation to treat drug‐resistant epilepsy: A randomized, controlled, crossover clinical trial
Epilepsia · 2025-01 · 66 (1) · 240-252
DOI: 10.1111/epi.18168 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 08.11.2024. Verfasst von Yuan-Yuan Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Epilepsy Center, Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Transcranial Magnetic Stimulation, Drug Resistant Epilepsy, Cerebellum. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Shaanxi Province Key Research and Development Project, National Natural Science Foundation of China, Shaanxi Province Special Support Program for Leading Talents in Scientific and Technological Innovation.
Abstract (Originalsprache)
Objective
Epilepsy is one of the most prevalent brain diseases. Approximately one third of patients consistently experience drug‐resistant epilepsy (DRE), a condition where seizures persist despite the use of antiseizure medications. Exploration of new therapies for DRE is urgently needed. In this single‐center, randomized, sham‐controlled, crossover clinical trial (NCT05042726), we aimed to investigate the effectiveness and safety of transcranial magnetic continuous theta burst stimulation (cTBS) targeting the cerebellum to treat DRE.
Methods
Patients with DRE for ≥2 years and a seizure frequency of ≥2 seizures per month were enrolled and randomized 1:1 to receive active stimulation followed by sham stimulation or vice versa. The bilateral cerebellum was targeted by navigated cTBS focusing on the cerebellar dentate nucleus, once daily on workdays for 2 weeks. The primary outcomes were the percentage of seizure reduction and 50% responder rate in the per‐protocol population within 2 months after treatment.
Results
Forty‐four patients were enrolled and randomized; 18 patients in the active stimulation‐first group and 20 in the sham stimulation‐first group were included in the final analysis. Active cTBS significantly reduced seizures compared to sham stimulation (difference in percentage of seizure reduction between treatments = 25%, 95% confidence interval [CI] = 5%–46%, p = .018). The 50% responder rate after active stimulation was significantly higher than that after sham stimulation (difference in 50% responder rate between treatments = 24%, 95% CI = 11%–40%, p = .029). Adverse events occasionally occurred during active stimulation (moderate headache in 5% of patients, tinnitus in 3% of patients, dizziness in 3% of patients) but resolved spontaneously within days after treatment completion. Significance This trial suggested that cTBS targeting the cerebellum was effective and well tolerated in the treatment of DRE. Further studies are warranted to confirm its effectiveness and mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Comprehensive Epilepsy Center, Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Neurology, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Health Statistics, Fourth Military Medical University, Xi'an, China.
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
ORCID-Profile: Xiu-Xiu Leng, Fang Yuan, Chang-Geng Song, Wen Jiang
Förderung
- Shaanxi Province Key Research and Development Project
- National Natural Science Foundation of China
- Shaanxi Province Special Support Program for Leading Talents in Scientific and Technological Innovation
- Discipline Promotion Project of Xijing Hospital
Zitieren
APA
Wang, Y. Y., Ma, L., Shi, X. J., Liu, Y., Wu, D. W., Hao, J. M., Leng, X. X., Jin, L., Yuan, F., Sun, Z. Q., Zhao, J. J., Wang, L., Shang, L., Wang, D. L., Song, C. G., & Jiang, W. (2025). Cerebellar transcranial magnetic stimulation to treat drug‐resistant epilepsy: A randomized, controlled, crossover clinical trial. Epilepsia, 66(1), 240-252. https://doi.org/10.1111/epi.18168
Vancouver
Wang YY, Ma L, Shi XJ, Liu Y, Wu DW, Hao JM, et al. Cerebellar transcranial magnetic stimulation to treat drug‐resistant epilepsy: A randomized, controlled, crossover clinical trial. Epilepsia. 2025;66(1):240-252. doi:10.1111/epi.18168
BibTeX
@article{Wang2025,
author = {Wang, Yuan-Yuan and Ma, Lei and Shi, Xiao-Jing and Liu, Yu and Wu, Dian-Wei and Hao, Jian-Min and Leng, Xiu-Xiu and Jin, Lang and Yuan, Fang and Sun, Zhong-Qing and Zhao, Jing-Jing and Wang, Ling and Shang, Lei and Wang, Duo-Lao and Song, Chang-Geng and Jiang, Wen},
title = {Cerebellar transcranial magnetic stimulation to treat drug‐resistant epilepsy: A randomized, controlled, crossover clinical trial},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {1},
pages = {240--252},
doi = {10.1111/epi.18168}
}
EUVIMED